• Mashup Score: 0

    Despite remarkable progress in asthma management and targeted therapies, challenges persist in effectively addressing difficult-to-treat asthma patients. Addressing modifiable factors, such as nonadherence, inadequate inhaler technique, and poorly controlled comorbidities such as those that are asthma mimickers, are necessary for adequate asthma control.1 Sanchis et al2 showed that adherence to asthma inhalers falls below that for medications for other chronic conditions and that correct inhaler use technique has remained unacceptably low over the last 40 years, all of which are a call to action in this space.

    Tweet Tweets with this article
    • In Current Issue (FREE)! Improving Difficult-to- #Treat #Asthma With #Digital #Inhaler #Adherence #Technologies: Are We There Yet? https://t.co/UfFapAV63w

  • Mashup Score: 5

    New Stock Epinephrine and Stock Inhaler Toolkits Improve Safety of Students with Anaphylaxis and Asthma

    Tweet Tweets with this article
    • New stock #epinephrine and stock #inhaler toolkits improve the safety of students with #anaphylaxis and #asthma. These toolkits provide critical emergency care for students just in time for back to school. #allergies #FoodAllergy https://t.co/55VgaXgMDM https://t.co/lQQ2K3Xbx5

  • Mashup Score: 0

    Several states in the United States (U.S.) have laws permitting stock inhalers, including short-acting beta-agonist inhalers, such as albuterol, and spacers to be prescribed to, dispensed to, and stocked in schools for use in students in respiratory distress, based on a protocol. This survey study a …

    Tweet Tweets with this article
    • #Pharmacists' #perspectives on school #stock #inhaler access for children https://t.co/eRi5AqXbJg https://t.co/RWyvWDwr5O

  • Mashup Score: 4

    The FDA approved a pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide for use as rescue medication among patients with asthma aged 18 years and older, according to a manufacturer-issued press release.According to the release, the FDA approved albuterol/budesonide (Airsupra; Avillion, AstraZeneca), previously known as PT027, in this patient population for

    Tweet Tweets with this article
    • The @US_FDA approved a pressurized metered-dose #inhaler with a fixed-dose combination of albuterol and budesonide for use as rescue medication among patients with #asthma aged 18 years and older, according to a press release from the manufacturer. https://t.co/6kbvWWlabK